Molecular determinants of context-dependent progesterone receptor action in breast cancer

BMC Medicine

Carol A Lange¹  Christy R Hagan¹ 

[1] Department of Medicine (Hematology, Oncology, and Transplantation) and the Department of Pharmacology, University of Minnesota, Masonic Cancer Center, 420 Delaware St SE, MMC 806, Minneapolis, MN 55455, USA

关键词: Signal transduction;    Progesterone receptor;    Post-translational modifications;    Breast cancer;   

Others  :  854971
DOI  :  10.1186/1741-7015-12-32

 received in 2013-10-17, accepted in 2014-01-21,  发布年份 2014

【 摘 要 】

The ovarian steroid hormone, progesterone, and its nuclear receptor, the progesterone receptor, are implicated in the progression of breast cancer. Clinical trial data on the effects of hormone replacement therapy underscore the importance of understanding how progestins influence breast cancer growth. The progesterone receptor regulation of distinct target genes is mediated by complex interactions between the progesterone receptor and other regulatory factors that determine the context-dependent transcriptional action of the progesterone receptor. These interactions often lead to post-translational modifications to the progesterone receptor that can dramatically alter receptor function, both in the normal mammary gland and in breast cancer. This review highlights the molecular components that regulate progesterone receptor transcriptional action and describes how a better understanding of the complex interactions between the progesterone receptor and other regulatory factors may be critical to enhancing the clinical efficacy of anti-progestins for use in the treatment of breast cancer.

【 授权许可】

   
2014 Hagan and Lange; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Brisken C: Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. Nat Rev Cancer 2013, 13:385-396.
• [2]Kraus WL, Montano MM, Katzenellenbogen BS: Cloning of the rat progesterone receptor gene 5′-region and identification of two functionally distinct promoters. Mol Endocrinol 1993, 7:1603-1616.
• [3]Hill KK, Roemer SC, Churchill ME, Edwards DP: Structural and functional analysis of domains of the progesterone receptor. Mol Cell Endocrinol 2012, 348:418-429.
• [4]Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, Chambon P: Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. Embo J 1990, 9:1603-1614.
• [5]Owen GI, Richer JK, Tung L, Takimoto G, Horwitz KB: Progesterone regulates transcription of the p21(WAF1) cyclin-dependent kinase inhibitor gene through Sp1 and CBP/p300. J Biol Chem 1998, 273:10696-10701.
• [6]Stoecklin E, Wissler M, Schaetzle D, Pfitzner E, Groner B: Interactions in the transcriptional regulation exerted by Stat5 and by members of the steroid hormone receptor family. J Steroid Biochem Mol Biol 1999, 69:195-204.
• [7]Cicatiello L, Addeo R, Sasso A, Altucci L, Petrizzi VB, Borgo R, Cancemi M, Caporali S, Caristi S, Scafoglio C, et al.: Estrogens and progesterone promote persistent CCND1 gene activation during G1 by inducing transcriptional derepression via c-Jun/c-Fos/estrogen receptor (progesterone receptor) complex assembly to a distal regulatory element and recruitment of cyclin D1 to its own gene promoter. Mol Cell Biol 2004, 24:7260-7274.
• [8]Hagan CR, Knutson TP, Lange CA: A common docking domain in progesterone receptor-B links DUSP6 and CK2 signaling to proliferative transcriptional programs in breast cancer cells. Nucleic Acids Res 2013, 41:8962-8942.
• [9]Knutson TP, Daniel AR, Fan D, Silverstein KA, Covington KR, Fuqua SA, Lange CA: Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression. Breast Cancer Res 2012, 14:R95. BioMed Central Full Text
• [10]McKenna NJ, Lanz RB, O’Malley BW: Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 1999, 20:321-344.
• [11]Daniel AR, Faivre EJ, Lange CA: Phosphorylation-dependent antagonism of sumoylation derepresses progesterone receptor action in breast cancer cells. Mol Endocrinol 2007, 21:2890-2906.
• [12]Lange CA, Shen T, Horwitz KB: Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc Natl Acad Sci U S A 2000, 97:1032-1037.
• [13]Weigel NL, Bai W, Zhang Y, Beck CA, Edwards DP, Poletti A: Phosphorylation and progesterone receptor function. J Steroid Biochem Mol Biol 1995, 53:509-514.
• [14]Daniel AR, Gaviglio AL, Czaplicki LM, Hillard CJ, Housa D, Lange CA: The progesterone receptor hinge region regulates the kinetics of transcriptional responses through acetylation, phosphorylation, and nuclear retention. Mol Endocrinol 2011, 24:2126-2138.
• [15]Pierson-Mullany LK, Lange CA: Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2. Mol Cell Biol 2004, 24:10542-10557.
• [16]Hagan CR, Regan TM, Dressing GE, Lange CA: CK2-dependent phosphorylation of progesterone receptors (PR) on Ser81 regulates PR-B isoform-specific target gene expression in breast cancer cells CK2. Mol Cell Biol 2011, 31:2439-2452.
• [17]Faivre EJ, Daniel AR, Hillard CJ, Lange CA: Progesterone receptor rapid signaling mediates serine 345 phosphorylation and tethering to specificity protein 1 transcription factors. Mol Endocrinol 2008, 22:823-837.
• [18]Ballare C, Uhrig M, Bechtold T, Sancho E, Di Domenico M, Migliaccio A, Auricchio F, Beato M: Two domains of the progesterone receptor interact with the estrogen receptor and are required for progesterone activation of the c-Src/Erk pathway in mammalian cells. Mol Cell Biol 2003, 23:1994-2008.
• [19]Boonyaratanakornkit V, Scott MP, Ribon V, Sherman L, Anderson SM, Maller JL, Miller WT, Edwards DP: Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Mol Cell 2001, 8:269-280.
• [20]Diaz Flaque MC, Vicario R, Proietti CJ, Izzo F, Schillaci R, Elizalde PV: Progestin drives breast cancer growth by inducing p21(CIP1) expression through the assembly of a transcriptional complex among Stat3, progesterone receptor and ErbB-2. Steroids 2013, 78:559-567.
• [21]Narayanan R, Adigun AA, Edwards DP, Weigel NL: Cyclin-dependent kinase activity is required for progesterone receptor function: novel role for cyclin A/Cdk2 as a progesterone receptor coactivator. Mol Cell Biol 2005, 25:264-277.
• [22]Beral V: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003, 362:419-427.
• [23]Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto GE, et al.: Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010, 304:1684-1692.
• [24]Birrell SN, Butler LM, Harris JM, Buchanan G, Tilley WD: Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer. FASEB J 2007, 21:2285-2293.
• [25]Courtin A, Communal L, Vilasco M, Cimino D, Mourra N, de Bortoli M, Taverna D, Faussat AM, Chaouat M, Forgez P, et al.: Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells. Breast Cancer Res Treat 2012, 131:49-63.
• [26]Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F: Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2005, 114:448-454.
• [27]Lyytinen H, Pukkala E, Ylikorkala O: Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol 2009, 113:65-73.
• [28]Lanari C, Lamb CA, Fabris VT, Helguero LA, Soldati R, Bottino MC, Giulianelli S, Cerliani JP, Wargon V, Molinolo A: The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer. Endocr Relat Cancer 2009, 16:333-350.
• [29]Lanari C, Molinolo AA: Progesterone receptors-animal models and cell signalling in breast cancer. Diverse activation pathways for the progesterone receptor: possible implications for breast biology and cancer. Breast Cancer Res 2002, 4:240-243. BioMed Central Full Text
• [30]Horwitz KB, Dye WW, Harrell JC, Kabos P, Sartorius CA: Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc Natl Acad Sci U S A 2008, 105:5774-5779.
• [31]Horwitz KB, Sartorius CA: Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: a hypothesis. J Clin Endocrinol Metab 2008, 93:3295-3298.
• [32]Joshi PA, Jackson HW, Beristain AG, Di Grappa MA, Mote PA, Clarke CL, Stingl J, Waterhouse PD, Khokha R: Progesterone induces adult mammary stem cell expansion. Nature 2010, 465:803-807.
• [33]Santen RJ: Risk of breast cancer with progestins: critical assessment of current data. Steroids 2003, 68:953-964.
• [34]Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ: Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 1999, 84:4559-4565.
• [35]Santen RJ: Menopausal hormone therapy and breast cancer. J Steroid Biochem Mol Biol 2013, 2013:2013.
• [36]Beleut M, Rajaram RD, Caikovski M, Ayyanan A, Germano D, Choi Y, Schneider P, Brisken C: Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci U S A 2010, 107:2989-2994.
• [37]Asselin-Labat ML, Shackleton M, Stingl J, Vaillant F, Forrest NC, Eaves CJ, Visvader JE, Lindeman GJ: Steroid hormone receptor status of mouse mammary stem cells. J Natl Cancer Inst 2006, 98:1011-1014.
• [38]Groshong SD, Owen GI, Grimison B, Schauer IE, Todd MC, Langan TA, Sclafani RA, Lange CA, Horwitz KB: Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1). Mol Endocrinol 1997, 11:1593-1607.
• [39]Clarke RB, Howell A, Anderson E: Estrogen sensitivity of normal human breast tissue in vivo and implanted into athymic nude mice: analysis of the relationship between estrogen-induced proliferation and progesterone receptor expression. Breast Cancer Res Treat 1997, 45:121-133.
• [40]Communal L, Vilasco M, Hugon-Rodin J, Courtin A, Mourra N, Lahlou N, Dumont S, Chaouat M, Forgez P, Gompel A: Ulipristal acetate does not impact human normal breast tissue. Hum Reprod 2012, 27:2785-2798.
• [41]Tanos T, Sflomos G, Echeverria PC, Ayyanan A, Gutierrez M, Delaloye JF, Raffoul W, Fiche M, Dougall W, Schneider P, et al.: Progesterone/RANKL is a major regulatory axis in the human breast. Sci Transl Med 2013, 5:182ra155.
• [42]Robertson JF, Willsher PC, Winterbottom L, Blamey RW, Thorpe S: Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. Eur J Cancer 1999, 35:214-218.
• [43]Hagan CR, Daniel AR, Dressing GE, Lange CA: Role of phosphorylation in progesterone receptor signaling and specificity. Mol Cell Endocrinol 2012, 357:43-49.
• [44]Dressing GE, Hagan CR, Knutson TP, Daniel AR, Lange CA: Progesterone receptors act as sensors for mitogenic protein kinases in breast cancer models. Endocr Relat Cancer 2009, 16:351-361.
• [45]Daniel AR, Faivre EJ, Lange CA: Phosphorylation-dependent antagonism of sumoylation derepresses progesterone receptor action in breast cancer cells. Mol Endocrinol 2007, 21:2890-2906.
• [46]Daniel AR, Lange CA: Protein kinases mediate ligand-independent derepression of sumoylated progesterone receptors in breast cancer cells. Proc Natl Acad Sci U S A 2009, 106:14287-14292.
• [47]Jozwik KM, Carroll JS: Pioneer factors in hormone-dependent cancers. Nat Rev Cancer 2012, 12:381-385.
• [48]Magnani L, Eeckhoute J, Lupien M: Pioneer factors: directing transcriptional regulators within the chromatin environment. Trends Genet 2011, 27:465-474.
• [49]Clarke CL, Graham JD: Non-overlapping progesterone receptor cistromes contribute to cell-specific transcriptional outcomes. PLoS One 2012, 7:e35859.
• [50]Obr AE, Grimm SL, Bishop KA, Pike JW, Lydon JP, Edwards DP: Progesterone receptor and Stat5 signaling crosstalk through RANKL in mammary epithelial cells. Mol Endocrinol 2013, 27:1808-1824.
• [51]Peters AA, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM, Jindal S, Segara D, Jia L, Moore NL, et al.: Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res 2009, 69:6131-6140.
• [52]Need EF, Selth LA, Harris TJ, Birrell SN, Tilley WD, Buchanan G: Research resource: interplay between the genomic and transcriptional networks of androgen receptor and estrogen receptor alpha in luminal breast cancer cells. Mol Endocrinol 2012, 26:1941-1952.
• [53]Giulianelli S, Vaque JP, Soldati R, Wargon V, Vanzulli SI, Martins R, Zeitlin E, Molinolo AA, Helguero LA, Lamb CA, et al.: Estrogen receptor alpha mediates progestin-induced mammary tumor growth by interacting with progesterone receptors at the cyclin D1/MYC promoters. Cancer Res 2012, 72:2416-2427.
• [54]Daniel AR, Gaviglio AL, Knutson TP, Ostrander JH, D'Assoro AB, Ravindranathan P, Peng Y, Raj GV, Yee D, Lange CA: Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes. Oncogene 2014. doi:10.1038/onc.2013.579. [Epub ahead of print]
• [55]Tawfic S, Yu S, Wang H, Faust R, Davis A, Ahmed K: Protein kinase CK2 signal in neoplasia. Histol Histopathol 2001, 16:573-582.
• [56]Guerra B, Issinger OG: Protein kinase CK2 in human diseases. Curr Med Chem 2008, 15:1870-1886.
• [57]Meggio F, Pinna LA: One-thousand-and-one substrates of protein kinase CK2? FASEB J 2003, 17:349-368.
• [58]Zhang Y, Beck CA, Poletti A, Edwards DP, Weigel NL: Identification of phosphorylation sites unique to the B form of human progesterone receptor. In vitro phosphorylation by casein kinase II. J Biol Chem 1994, 269:31034-31040.
• [59]Castelli M, Camps M, Gillieron C, Leroy D, Arkinstall S, Rommel C, Nichols A: MAP kinase phosphatase 3 (MKP3) interacts with and is phosphorylated by protein kinase CK2alpha. J Biol Chem 2004, 279:44731-44739.
• [60]Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70.
• [61]Hilton HN, Graham JD, Kantimm S, Santucci N, Cloosterman D, Huschtscha LI, Mote PA, Clarke CL: Progesterone and estrogen receptors segregate into different cell subpopulations in the normal human breast. Mol Cell Endocrinol 2012, 361:191-201.
• [62]Fuqua SA, Wiltschke C, Zhang QX, Borg A, Castles CG, Friedrichs WE, Hopp T, Hilsenbeck S, Mohsin S, O’Connell P, et al.: A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res 2000, 60:4026-4029.
• [63]Pooley KA, Healey CS, Smith PL, Pharoah PD, Thompson D, Tee L, West J, Jordan C, Easton DF, Ponder BA, et al.: Association of the progesterone receptor gene with breast cancer risk: a single-nucleotide polymorphism tagging approach. Cancer Epidemiol Biomarkers Prev 2006, 15:675-682.
• [64]De Vivo I, Huggins GS, Hankinson SE, Lescault PJ, Boezen M, Colditz GA, Hunter DJ: A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk. Proc Natl Acad Sci U S A 2002, 99:12263-12268.
• [65]Terry KL, De Vivo I, Titus-Ernstoff L, Sluss PM, Cramer DW: Genetic variation in the progesterone receptor gene and ovarian cancer risk. Am J Epidemiol 2005, 161:442-451.
• [66]Pathiraja TN, Shetty PB, Jelinek J, He R, Hartmaier R, Margossian AL, Hilsenbeck SG, Issa JP, Oesterreich S: Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients. Clin Cancer Res 2011, 17:4177-4186.
• [67]Romieu G, Maudelonde T, Ulmann A, Pujol H, Grenier J, Cavalie G, Khalaf S, Rochefort H: The antiprogestin RU486 in advanced breast cancer: preliminary clinical trial. Bull Cancer 1987, 74:455-461.
• [68]Klijn JG, de Jong FH, Bakker GH, Lamberts SW, Rodenburg CJ, Alexieva-Figusch J: Antiprogestins, a new form of endocrine therapy for human breast cancer. Cancer Res 1989, 49:2851-2856.
• [69]Perrault D, Eisenhauer EA, Pritchard KI, Panasci L, Norris B, Vandenberg T, Fisher B: Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 1996, 14:2709-2712.
• [70]Jonat W, Bachelot T, Ruhstaller T, Kuss I, Reimann U, Robertson JF: Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer. Ann Oncol 2013, 24:2543-2548.
• [71]Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, Lee EY: Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 2006, 314:1467-1470.
• [72]Encarnacion CA, Ciocca DR, McGuire WL, Clark GM, Fuqua SA, Osborne CK: Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat 1993, 26:237-246.
• [73]Johnston SR, Saccani-Jotti G, Smith IE, Salter J, Newby J, Coppen M, Ebbs SR, Dowsett M: Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 1995, 55:3331-3338.
• [74]Hayes E, Nicholson RI, Hiscox S: Acquired endocrine resistance in breast cancer: implications for tumour metastasis. Front Biosci (Landmark Ed) 2011, 16:838-848.
• [75]Cleator SJ, Ahamed E, Coombes RC, Palmieri C: A 2009 update on the treatment of patients with hormone receptor-positive breast cancer. Clin Breast Cancer 2009, 9:S6-S17.
• [76]Pierson-Mullany LK, Skildum A, Faivre E, Lange CA: Cross-talk between growth factor and progesterone receptor signaling pathways: implications for breast cancer cell growth. Breast Dis 2003, 18:21-31.
• [77]Mote PA, Balleine RL, McGowan EM, Clarke CL: Colocalization of progesterone receptors A and B by dual immunofluorescent histochemistry in human endometrium during the menstrual cycle. J Clin Endocrinol Metab 1999, 84:2963-2971.
• [78]Mote PA, Bartow S, Tran N, Clarke CL: Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis. Breast Cancer Res Treat 2002, 72:163-172.
• [79]Mote PA, Graham JD, Clarke CL: Progesterone receptor isoforms in normal and malignant breast. Ernst Schering Found Symp Proc 2007, 1:77-107.
• [80]Graham JD, Yeates C, Balleine RL, Harvey SS, Milliken JS, Bilous AM, Clarke CL: Characterization of progesterone receptor A and B expression in human breast cancer. Cancer Res 1995, 55:5063-5068.
• [81]Boonyaratanakornkit V, McGowan E, Sherman L, Mancini MA, Cheskis BJ, Edwards DP: The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle. Mol Endocrinol 2007, 21:359-375.
• [82]Clemm DL, Sherman L, Boonyaratanakornkit V, Schrader WT, Weigel NL, Edwards DP: Differential hormone-dependent phosphorylation of progesterone receptor A and B forms revealed by a phosphoserine site-specific monoclonal antibody. Mol Endocrinol 2000, 14:52-65.
• [83]Qiu M, Lange CA: MAP kinases couple multiple functions of human progesterone receptors: degradation, transcriptional synergy, and nuclear association. J Steroid Biochem Mol Biol 2003, 85:147-157.
• [84]Qiu M, Olsen A, Faivre E, Horwitz KB, Lange CA: Mitogen-activated protein kinase regulates nuclear association of human progesterone receptors. Mol Endocrinol 2003, 17:628-642.
• [85]Faivre EJ, Lange CA: Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells. Mol Cell Biol 2007, 27:466-480.
• [86]Lanari C, Wargon V, Rojas P, Molinolo AA: Antiprogestins in breast cancer treatment: are we ready? Endocr Relat Cancer 2012, 19:R35-R50.